| Project/Area Number |
15591347
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
General surgery
|
|---|
| Research Institution | Yamaguchi University |
|---|
Principal Investigator |
ENOKI Tadahiko Yamaguchi University, Hospital, Assistant Professor, 医学部附属病院, 講師 (80311819)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
HAMANO Kimikazu Yamaguchi Universyty, Faculty of Medicine, Professor, 医学部, 教授 (60263787)
ITO Hiroshi Yamaguchi University, Hospital, Research Assistant, 医学部附属病院, 助手 (90363100)
|
|---|
| Project Period (FY) |
2003 – 2005
|
| Project Status |
Completed (Fiscal Year 2005)
|
| Budget Amount *help |
¥3,400,000 (Direct Cost: ¥3,400,000)
Fiscal Year 2005: ¥800,000 (Direct Cost: ¥800,000)
Fiscal Year 2004: ¥1,100,000 (Direct Cost: ¥1,100,000)
Fiscal Year 2003: ¥1,500,000 (Direct Cost: ¥1,500,000)
|
|---|
| Keywords | xenotransplantation / tolerance / CD27 / mixed chimerism / 移植免疫 / costimulatory blockade / キメリズム |
|---|
| Research Abstract |
Background :
Costimulatory blockade can obviate the need for repeated T cell depletion or thymic irradiation, CD4 depletion in an nonmyeloablative allogeneic bone marrow engraftment that leads to mixed chimerism and donor-specific tolerance. However, the potential of mixed chimerism against xenotransplantation has not been evaluated. Here we analyze the role of mixed chimerism and CD27-CD70 blockade in xenogeneic heart transplantation.
Methods :
C57BL/6 mice received anti-CD8(2.43) or anti-CD27 and/or NK-1.1(PK136) plus Thy-1.2(30-H12)mAbs on day-1, total body irradiation(TBI ; 3 Gy )(day 0), and 100×10^6 xenogeneic F344 rat bone marrow cells(BMC). One injection of anti-CD40L mAb (MR1 ; 2mg, day 0) was also given. Heterotopic heart transplantation was performed on day 0 after BMT to assess induction of donor-specific tolerance. Donor cell engraftment was measured by flow cytometry (FCM) analysis.
Results :
Mice that received no treatment (n=6) rejected rat heart graft by 8 days. Mice receiv
… More
ed TBI alone (n=6) showed slightly prolongation of donor heart (MST, median survival time=12). Mice received anti- CD8 mAb (day-1), MR1 (day 0) plus TBI/BMT(day 0)(n=6) and mice received MR1 (day 0) plus TBI/BMT(day 0)(n=5) did not developed long-term mixed chimerism, and grafted heart were rejected soon after transplantation (MST=35day and 33 day, respectively). Mice received anti-NK1.1/Thy1.2 mAbs (day-1), MR1(day 0) plus TBI/BMT(day 0)(n=6) developed mixed chimerism only early after BMT, and showed prolongation of graft survival (MST=61 day). Mice received anti-CD8/NK1.1/Thy1.2 mAbs (day-1), MR1 (day 0) plus TBI/BMT(day 0)(n=6) initially developed mixed chimerism, however, those chimerism was also disappear by 10 weeks post BMT. Those mice accepted donor rat heart (MST>250 days). Mice received anti-CD27 antibody plus MR1/NK1.1/Thy1.2 mAb did not developed mixed chimerism and tolerance(n=4). In allotransplantation model, anti-CD27 plus MR1 could not developed mixed chimerism (n=5).
Conclusion :
Blocking of CD27-CD70 interaction could not prevent CD8 mediated allo and xeno rejection in transplantation model using mixed chimerism. Less
|
